This Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $388,193 to EDI Therapeutics LLC to develop a novel "fibronectin matrix mimetic" therapeutic called Chimectin for treating chronic diabetic wounds. The funds will be used to (i) fully characterize the tissue responses to Chimectin in diabetic mouse models, and (ii) test its efficacy in a diabetic porcine dermal wound model. The goal is to advance Chimectin to clinical trials to evaluate its ability to stimulate wound healing in diabetic patients. This research aligns with the NIDDK program's focus on supporting innovative approaches to addressing complex health challenges related to diabetes, digestive systems, and kidney diseases.
Generated 2/25/25, 5:35 AM